Imiglucerase biosimilar - ProfarmaAlternative Names: PF-13
Latest Information Update: 17 Jun 2015
At a glance
- Originator Profarma
- Class Glucosidases
- Mechanism of Action Glucosylceramidase replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Gaucher's disease
Most Recent Events
- 17 Jun 2015 Early research in Gaucher's disease in Lithuania (Parenteral) (Profarma pipeline, June 2015)